Is AveXis part of Novartis?

Since its acquisition in May 2018, AveXis has been a high-profile and extremely successful investment for Novartis, evolving from a clinical-stage to a commercial organization. The most widely used gene therapy in the world, Zolgensma treats spinal muscular atrophy (SMA), the leading genetic cause of infant death.

Who is the owner of AveXis?

Novartis
Novartis Gene Therapies/Parent organizations

Why are you interested in Novartis gene therapies?

AveXis is now Novartis Gene Therapies. Novartis Gene Therapies is dedicated to developing and commercializing gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases.

Where is Novartis gene therapies?

We are headquartered in Bannockburn, IL with another location in Deerfield, IL. Our manufacturing facilities are located in Libertyville, IL, Durham, NC and Longmont, CO. Our research site is located in San Diego, CA.

What kind of company is AveXis, Inc.?

AveXis, Inc. operates as a clinical-stage gene therapy company. The Company focuses on developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. AveXis conducts business in the United States. NO. OF EMPLOYEES

What kind of disease does AveXis treat?

AveXis has several ongoing clinical studies for the treatment of SMA, an inherited neurodegenerative disease caused by a defect in a single gene, the survival motor neuron (SMN1).

When did AveXis change its name to Novartis?

In September 2020, AveXis changed its name to Novartis Gene Therapies. ^ Speights, Keith The Motley Fool, May 30, 2019 Bothered by the Price Tag of a $2.1 Million Drug?

Who is the Chief Scientific Officer of AveXis?

According to a regulatory filing, Allan Kaspar joined AveXis in January 2014 and served as vice president of research and development. Brian Kaspar provided consulting services to AveXis from January 2014 to December 2015 and became chief scientific officer in June 2015.